pharmaphorum

JUNE 3, 2021

This article appears in our digital magazine Deep Dive: Market Access 2021. Lots of buzzwords feature: flexible, agile, robust, future proof, rapid access. That’s not all that new, but perhaps the change in emphasis is welcome. • Read the full article in pharmaphorum’s Deep Dive digital magazine.

Documentation 98

Documentation 98

pharmaphorum

MAY 17, 2021

This article appears in full in our digital magazine Deep Dive: Market Access 2021. This will help drive consistent processes, effective assessments and enable early access to high-value medicines. Read below for a sneak-peak: The reimbursement landscape in Europe is complex.

92

92

pharmaphorum

JUNE 21, 2022

Whether it’s the levelling up agenda, economics, social care and population health management and more, ICSs are front and centre of everything,” Steven Ferguson, head of Market Access UK and Ireland, IQVIA. The post ICSs: improving patient and market access at a local level appeared first on.

52

52

pharmaphorum

OCTOBER 14, 2022

In this article, Research Partnership reviews why the path to commercialisation for the half a dozen approvals in Europe over the last few years has not been smooth, and shares feedback gathered from our payer network on the outlook for gene therapy market access in Europe, especially considering the shift to more prevalent diseases.

Communication 93

Communication 93

pharmaphorum

DECEMBER 2, 2022

With myriad new technologies and tools hitting the market, there is no doubt that digital health is transforming the way that we deliver and receive healthcare. However, as the market begins to correct itself, where does digital health go from here? Read Deep Dive: Digital Health 2022 in full.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

pharmaphorum

DECEMBER 14, 2020

As this issue’s title suggests, patient centricity is about more than just talking points and marketing strategies – it requires companies to truly listen to, engage with and partner with the patients they serve, and in putting this month’s Deep Dive together it’s been great to see that so many pharma firms are now taking this to heart.

Pharmaceutical Companies 73

Pharmaceutical Companies Pharmaceutical Companies FDA 73

pharmaphorum

JUNE 7, 2022

In my role as head of market access at Sanofi UK and Ireland, I strive to address challenges around matching treatment value to patient access, and I am passionate about delivering evidence to ensure patients can receive the most appropriate treatments for their condition.

52

52

pharmaphorum

OCTOBER 4, 2022

For life science companies, it is more important than ever to understand the market access landscape they are launching in and review how commercial and engagement strategies align with the needs of today’s customers.

Communication 52

Communication 52

pharmaphorum

MAY 12, 2021

This article appears in full in Deep Dive: Market Access 2021. ” • Read the full article in pharmaphorum’s Deep Dive digital magazine. For example, did they already have e-consents in place, or were they completely reliant on face-to-face and are now having to start from scratch?”

74

74

pharmaphorum

SEPTEMBER 17, 2020

OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharma. Subscribe to future issues of Deep Dive. The post Deep Dive: Communications 2020 appeared first on. Responding to dynamic shifts in value communications.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 4, 2021

A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how these products can find a smoother path to market. This article appears in our free digital magazine Deep Dive: Market Access 2021.

Compounding 45

Compounding FDA 45

pharmaphorum

NOVEMBER 2, 2020

Most of the digital health experts we spoke to for this issue of Deep Dive made one thing clear – no one can really say what the future holds for digital tech in the pharma and healthcare industries. Thriving in COVID-19 with flexible marketing strategies. Subscribe to future issues of Deep Dive.

Pharmaceutical Companies 58

Pharmaceutical Companies Pharmaceutical Companies 58

pharmaphorum

MARCH 22, 2022

We show how companies can leverage and create efficiencies from the full scope of available data obtainable within each of its teams, whether medical affairs, market access , or GHEORE,” says Cherian. The post Using cross-functional teams to develop a product’s value story appeared first on.

Communication 52

Communication 52

pharmaphorum

JUNE 14, 2021

This article appears in our free digital magazine Deep Dive: Market Access 2021. Fighting for access. Sanders has been on metreleptin treatment herself for over 10 years, and from the start has been involved in fighting for access to the drug, engaging with the pharma companies, clinical researchers, and NICE.

Communication 102

Communication 102

pharmaphorum

MARCH 17, 2022

The global market for life sciences is changing rapidly. But when it comes to marketing new therapies, the seemingly complex nature of global markets can be intimidating, with regulatory, cultural and language insight required to commercialise a brand image across different markets.

52

52

pharmaphorum

MARCH 15, 2022

With digital engagement rapidly overtaking traditional models, life science teams must equip themselves with a means to engage patients in a virtual setting that’s easy to access and available when they are. Marketing Permissions. We use Mailchimp as our marketing platform. Real-world examples of patient engagement success.

98

98

pharmaphorum

FEBRUARY 26, 2021

From animal processing, to cell therapy and AI, Tim Mullane, president, and chief operating officer tells pharmaphorum how FUJIFILM Irvine Scientific has evolved to become one of the top manufacturers of cell culture media. • Read the latest issue Deep Dive: Research and Development 2021 in full.

Vaccines 58

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 58

pharmaphorum

NOVEMBER 16, 2022

Regulatory and market access submissions. Here, we examine how patients view the impact from projects and their experiences of discussing impact measurement with life science companies. • Read the full article in pharmaphorum’s Deep Dive digital magazine. Clinical trial design. Product support and information.

52

52

pharmaphorum

NOVEMBER 25, 2021

Why is a new access model so pressing, and has the pandemic accelerated the situation? Although the need for a change in the market access model predates the arrival of COVID-19, the pandemic has accelerated this process. The post Time for a new model in patient access appeared first on. Yes, it has.

52

52

pharmaphorum

OCTOBER 21, 2021

The company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of pharma’s approach to communications and commercialisation. Overseeing all of this is as the company’s senior vice president for major markets is Catherine Owen.

Communication 52

Communication 52

pharmaphorum

MAY 26, 2021

Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive Insight discuss how a holistic, multi-stakeholder approach can help companies overcome access barriers at all stages. You essentially need to take a three-by-three matrix view.

52

52

pharmaphorum

AUGUST 4, 2022

“There has been a surge in the number of biomarkers discovered through a broader understanding of the molecular pathways involved in the development of cancer, both across solid and liquid tumours,” explains Orlaith Brennan, market development director, Patient & Market Access at IQVIA. “In

52

52

pharmaphorum

MAY 14, 2021

This article appears in our digital magazine, Deep Dive: Market Access 2021. This additional effort could lead to poorer patient access. “It It is also possible that companies may prefer to enter the EU market through the EMA process and avoid additional processes involving the MHRA and NICE.

Documentation 58

Documentation Pharmaceutical Companies Pharmaceutical Companies 58

pharmaphorum

MAY 10, 2021

This article appears in full in this month’s Deep Dive digital magazine on Market Access. IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. The post A year on: pandemic driven trends in HCP engagement appeared first on.

Hospitals 84

Hospitals 84

pharmaphorum

OCTOBER 7, 2020

OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies. Value in healthcare is a continually changing concept. The post Responding to dynamic shifts in value communications appeared first on.

Communication 68

Communication Pharmaceutical Companies Pharmaceutical Companies 68

pharmaphorum

JUNE 18, 2021

This article appears in our free digital magazine Deep Dive: Market Access 2021. These included raising awareness, access to care, collaboration and innovation, and digital. The goal was to provide a platform for a global patient organisation and a meeting of groups who may have never met.

52

52

pharmaphorum

JANUARY 20, 2023

For millions of people around the world living with infectious disease and cancer, the arrival of a new prophylactic or therapeutic vaccine on the market can be life changing. But in order for a treatment to reach patients, it needs to be launched.

Vaccines 52

Vaccines 52

pharmaphorum

NOVEMBER 26, 2021

As companies are increasingly forced to persuade budget-holders of a drug’s cost-effectiveness to ensure post-approval market access, RWD can play a central role. The post Leveraging real-world data to meet payers’ needs appeared first on.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

NOVEMBER 10, 2020

Digital therapeutics are gaining momentum worldwide and offer developers, including pharma, both a huge opportunity and a stimulating market access challenge, say Olaf Schoeman and Emanuele Arcà. The post Germany’s digital health changes will boost digital therapeutics in Europe appeared first on.

Pharmaceutical Companies 72

Pharmaceutical Companies Pharmaceutical Companies 72

Fuld

JULY 26, 2022

Following a decade-long bull run, exuberance in the public markets is in its final stages. This is a consequence of influential paradigm shifts – not just in financial markets, but in the economic outlook, geopolitical changes, and the rising interest rate regime – all of which are putting downward pressure on assets of all classes.

Immunization 59

Immunization 59

pharmaphorum

JUNE 8, 2021

Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”.

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunization 105

Pharmaceutical Technology

JUNE 29, 2022

Additionally, pricing and access for rare disease therapies continue to be scrutinized closely. In a series of data-driven deep dives, we will examine how the development of orphan drug therapies has evolved over the years, and use the FDA’s orphan drug program as a barometer of these advances.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

pharmaphorum

JULY 26, 2021

After all, pharma are the experts in getting drugs through trials and onto the market, right? Healthcare systems and patients are suffering the consequences, as drug prices and times to market increase, and access to treatments is consequently hindered in the context of an ageing population carrying an ever-rising chronic disease burden.

52

52

pharmaphorum

JUNE 22, 2021

This article appears in our free digital magazine Deep Dive: Market Access 2021. So we try and invite different people to every meeting we’ve done and come up with tangible goals from them.”. • Read the full article in pharmaphorum’s Deep Dive digital magazine. Read below for a preview.

Communication 52

Communication 52

Roots Analysis

JANUARY 2, 2024

Patient engagement solutions include electronic medical records (HER), telemedicine and patient portals, which improve communication and help patients access their healthcare information. What are Applications of Patient Engagement? Detailed information on all suggestions to improvise the overall app is available in the full report.

Health and Personal Care Stores 40

Health and Personal Care Stores Medical Records Prescription Management Communication 40

ISPE

MAY 2, 2023

First, this conference has been developed by the best possible program committee: the committee members have deep knowledge of the content areas, are attuned with the latest industry trends, and come from all aspects of the broad pharma and life sciences community. you will see few changes to the conference layout this year.

98

98

pharmaphorum

MAY 25, 2021

The Collective says it will “lead a conversation on maintaining this early progress and realising the potential of future therapies as the technology progresses” – including tackling barriers to access and “translating positive public attitudes towards the science into public support for its use in treatments in the NHS”. About the author.

88

88